The deal follows the June approval of the NerPharMa facility for the production of pixantrone by the Italian Medicines Agency (AIFA).
“We are pleased to have reached an agreement with NerPharMa for the long-term manufacture of pixantrone", said Craig Philips, president of CTI. Securing supply of the product is part of CTI’s commercialisation efforts.
CTI is preparing to submit a marketing authorization application for pixantrone in the European Union. It also plans to start a Phase III trial of pixantrone in patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma in the US.